JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 93 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $176,490 | -54.0% | 159,000 | -3.0% | 0.01% | -50.0% |
| Q3 2022 | $384,000 | +77.8% | 164,000 | +424.0% | 0.01% | +150.0% |
| Q2 2020 | $216,000 | -86.0% | 31,300 | -90.4% | 0.00% | -88.6% |
| Q1 2020 | $1,546,000 | -21.6% | 325,500 | +44.1% | 0.04% | +29.6% |
| Q4 2019 | $1,972,000 | +285.9% | 225,900 | +47.1% | 0.03% | +285.7% |
| Q3 2019 | $511,000 | -58.4% | 153,600 | -38.0% | 0.01% | -56.2% |
| Q2 2019 | $1,227,000 | -12.9% | 247,900 | +9.2% | 0.02% | -11.1% |
| Q1 2019 | $1,408,000 | +40.1% | 227,100 | -23.9% | 0.02% | +38.5% |
| Q4 2018 | $1,005,000 | -23.9% | 298,300 | +46.7% | 0.01% | 0.0% |
| Q3 2018 | $1,321,000 | – | 203,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 9,200,349 | $64,402,000 | 44.86% |
| TRV GP III, LLC | 3,048,780 | $21,342,000 | 1.83% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 406,665 | $2,847,000 | 1.65% |
| Sofinnova Investments, Inc. | 925,280 | $6,477,000 | 0.39% |
| Omega Fund Management, LLC | 334,965 | $2,345,000 | 0.35% |
| Yorktown Management & Research Co Inc | 49,200 | $344,000 | 0.31% |
| Woodline Partners LP | 940,902 | $6,586,000 | 0.18% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 51,000 | $357,000 | 0.09% |
| HORIZON FINANCIAL SERVICES, LLC | 12,005 | $84,000 | 0.08% |
| Gyon Technologies Capital Management, LP | 26,893 | $188,000 | 0.06% |